INTRODUCTION
The inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal (GI) tract characterized by alternating periods of remission and relapse [1] . These diseases represent a large group of inflammatory disorders, the most common being Crohn's disease (CD) and ulcerative colitis (UC) [2, 3] . CD can affect any part of the GI tract and has the classic symptoms of fatigue, prolonged diarrhea (with or without bleeding), abdominal pain, weight loss, and fever [4, 5] . UC is a type of chronic inflammation restricted to the colon; however, the entire large intestine may be affected [6] . Affected patients show symptoms such as rectal bleeding, frequent bowel movements, tenesmus, rectal mucus discharge, and abdominal pain [5] . The etiology of IBDs is still not fully understood; however, it is believed that environmental, genetic and immunologic factors have important roles in their occurrence and progression [4, 7] . Emerging models in the study of IBD pathogenesis suggest three key disease development factors: (1) breaking the intestinal barrier function; (2) lamina immune cell exposure to luminal contents; and (3) exacerbation of immune response. However, the factors responsible for initiation and perpetuation of the cycle leading to exacerbation of the disease are still unclear [8, 9] . A combination of genetic and environmental factors may foment changes in the intestinal mucosal barrier function; this allows translocation of luminal antigens (commensal bacteria or microbial products) into the intestinal wall, and consequent immune cell activation and excessive production of cytokines, causing the acute phase of inflammation. If the acute inflamma tory process is not resolved by antiinflammatory mechanisms and suppression of proinflammatory cytokines, chronic intestinal inflammation develops. This can lead to tissue destruction and complications of the disease [10] . Conventional treatments are aimed at reducing inflammation and consequent abnormal symptom relief. Patients with UC are treated with aminosalicylates, corticosteroids, and immunomodulatory drugs [11] . Natural products have become the most attractive source of new drugs for the treatment and prevention of diseases and their use is constantly expanding worldwide. A variety of herbal medicines have been shown to produce promising results in the treatment of peptic ulcer and IBD [1114] . Combretum duarteanum (C. duarteanum, Cd) Cambess., the species selected for this study, is popularly known as "mufumbo, cipiúba, cipaúba". This shrubby species is exclusive to South America with registrations in Bolivia, Paraguay, and Brazil. It occurs in the northern and northeastern regions of Brazil, being associated with the "caatinga" biome [15, 16] . In folk medicine, C. duarteanum is used to treat pain, inflammation and GI tract disorders, which justifies its selection, using ethnopharmacological indication as the criterion of choice. Phytochemical studies suggest the presence of flavonoids and triterpenes, whose pharmacological effects have been attributed [1618] . C. duarteanum has presented in vitro and in vivo antiinflammatory, antinociceptive, and antioxidant capacities [15] . Quintans et al [17] demonstrated orofacial nociceptive activity as promoted by the hexane phase and Fridelin terpenes, isolated from the species studied.
de Morais Lima et al [16, 19] demonstrated gastro protective and antiulcer activity in C. duarteanum in different models of acute ulcer induction (acidified ethanol, ethanol, nonsteroidal antiinflammatory drugs (commonly known as NSAIDs), stress, pylorus ligature, acetic acid) in animals. Previous studies demonstrated low toxicity and no change of liver enzymes in animals treated with the tested plant sample for 15 d in acid aceticinduced gastric ulcer model [19] . Given the need for new IBD therapies, this study aimed to evaluate the intestinal antiinflammatory activity promoted by the species C. duarteanum, validating its popular use and contributing to the search for new therapies for diseases that affect the GI tract.
MATERIALS AND METHODS

Reagents
The drugs and reagents were prepared immediately before use. The following drugs were used: trinitro benzenesulfonic acid (TNBS) (SigmaAldrich), ketamine 5% (Vetanarcol), xilazine 2% (Dorcipec), ethanol (Merck ® ), Tween 80 (Merck ® ), sodium chloride (Sigma Aldrich). TNFα, IL1β and IL10 in enzymelinked immunosorbent assay (ELISA) kits were provided by R&D Systems Inc.
Plant material
Plant samples used in intestinal antiinflammatory activity research experiments in rats were obtained from the leaves of C. duarteanum Cambess., collected at Serra Branca City, Paraíba State, Brazil, in 2010. The species was identified by Dr. Maria Fatima Agra and a voucher specimen (No. 6767) was deposited in the Herbarium Prof. Lauro Pires Xavier (JPB) at the Universidade Federal da Paraíba.
The ethanolic extract (CdEtOHE) and the hexane phase (CdHexP) obtained from the leaves of C. duarteanum Cambess. were provided by Dr. Josean Fechine Tavares and his group, all of PgPNSB/UFPB.
The dried leaves (5 kg) were powdered, extracted with ethanol, stirred, and macerated at room tem perature for approximately 48 h, with the procedure being repeated three times. The solvent was fully evaporated under reduced pressure, and the extract (yield of 200 g) was concentrated. The CdEtOHE was subjected to liquidliquid partition with the following solvents: hexane, chloroform (CHCl3), and ethyl acetate (EtOAc), obtaining their respective phases. This step was repeated to secure the required quantity for the study.
Pharmacological assays
Investigation of Cd-EtOHE and Cd-HexP effects on acute phase intestinal inflammation (TNBS)-induced in rats: The intestinal antiinflammatory activity of CdEtOHE and CdHexP was assessed in rats using the Morris et al [20] method. Male Wistar rats (n = 58) fasted for 24 h were divided into four groups: noncolitic, colitic, CdEtOHE and CdHexP. The animals were anesthetized for rectal administration of TNBS (2,4,6trinitrobenzene sulfonic acid) 10 mg solubilized in 0.25 mL of 50% v/v ethanol. The induction of inflammation was performed with the aid of a probe (2mm diameter), which was inserted about 8 cm into the rectum of the animal. After TNBS administration, animals were maintained upside down for 15 min to enable total absorption of the administered inducing agent. The noncolitic group underwent the same procedures but they did not receive TNBS. Each group of rats was pretreated with vehicle (12% Tween 80), CdEtOHE (31.25, 62.5, 125, 250 mg/kg) or CdHexP (31.25, 62.5, 125, 250 mg/kg), at 48, 24 and 1 h prior to administration of TNBS/50% ethanol, and at 24 h after colitis induction. At 48 h after inducing inflammation, the animals were euthanized and colonic segments were removed, opened, washed, and photographed for quantification of ulcerative lesion area (ULA) and macroscopic score evaluation of the intestinal inflammatory process. Analysis of the extent of intestinal injury was performed according to the scale described previously by Bell et al [21] . General parameters such as diarrhea and the colon weight/ length ratio were also evaluated. The most effective doses obtained in this model were used in the chronic model with relapse of UC in rats.
Investigation of Cd-EtOHE and Cd-HexP effects in the chronic phase with intestinal inflammation relapse induced by TNBS in rats: Male Wistar rats (n = 79) were divided into noncolitic, colitic, CdEtOHE and CdHexp groups. After 24 h of fasting, induction of intestinal inflammation was performed with TNBS (10 mg/0.25 mL ethanol 50% v/v, rectally) [20] . At 24 h after initial induction, the animal groups were treated orally with 12% Tween 80 solution (noncolitic and colitic), Cd EtOHE (125 mg/kg) or CdHexP (62.5 mg/kg). On day 14 after the first induction, the second administration using ELISA assay kits (DuoSet ® ; R & D Systems Inc.). The concentrations of the cytokines in relation to the amount of total protein was quantified by bicinchoninic acid method [24] .
Immunohistochemical analysis cyclooxygenase-2, proliferating cell nuclear antigen, and superoxide dismutase expression Histological samples were incubated with anticyclo oxygenase2 (COX2) secondary antibody (marker for assessing antiinflammatory effect), antiproliferating cell nuclear antigen (PCNA) (cell division marker to assess potential for regeneration), and antisuperoxide dismutase (SOD) (marker to evaluate the antioxidant effect). The positively stained cells were counted for the various immunohistochemical reactions in a fixed number of fields by means of an image analyzer (QWin Standard Version 3.1.0; Leica) coupled to the Leica DM microscope. They were photographed and analyzed by AVSoft program Bioview Spectra and Seeker 4.0.
Animal care and use statement
The experimental protocols were approved by the Committee for Ethics in Animal Experimentation (CEPA/ LTF/UFPB) under number 1112/10. Male Wistar albino rats (180250 g) from the "Prof. Thomas George Vivarium" of LTF/UFPB were fed a certified Presence ® diet, with free access to water under fixed conditions of illumination (12/12 h light/dark cycle), humidity (60% ± 1.0%), and temperature (21.5 ± 1.0 ℃). Fasting was used prior to all assays since standard drugs were administered orally (by gavage) or by intrarectal route, using a 12% solution of Tween 80 (10 mL/kg) as the vehicle. The animals were kept in cages with raised, widemesh floors to prevent coprophagy.
Statistical analysis
Results with parameter values (inflammatory bowel lesion area and weight/length ratio) were subjected to analysis of variance (ANOVA) followed by Dunnett's or Tukey test, and expressed as mean ± SD of the average. In quantitation assays of antioxidant enzymes, cytokines and MPO values obtained were presented as mean ± standard error of mean (SEM).
For nonparametric values (score of intestinal inflammation), the KruskalWallis test (ANOVA, Dunn's posttest) was used. The results were expressed as median (minimummaximum). Data were analyzed using the software GraphPad Prism 6.0, and the significance level was set at p < 0.05.
RESULTS
Investigation of Cd-EtOHE and Cd-HexP effect on induced acute phase intestinal inflammation (TNBS) in rats
A significant reduction in the intestinal ULA for rats (relapse) was performed with TNBS (10 mg/0.25 mL ethanol 50% v/v, rectally) to mimic recurrent relapses in IBDs in humans.
General parameters such as diarrhea, water and food intake, and body weight were recorded daily throughout the treatment period. At day 21 all animals were euthanized, the colon removed, opened, and washed for macroscopic lesion analysis and evaluation of the intestinal inflammatory process [21] . Collection of material for biochemical and histological analysis was also performed. The samples were stored at 80 ℃ for evaluation of myeloperoxidase (MPO) and cytokines involved in intestinal inflammation.
Histological analysis
Colonic segments intended for light microscopy were collected. For this, the tissues were fixed in Alfac solution for 24 h at room temperature. Afterwards, the pieces were kept in 80% alcohol until the block assembly time. The pieces were dehydrated and embedded in paraplast forming blocks, and then cut to 10mm thickness for mounting on slides. These were stained with hematoxylin and eosin for morphological analysis [22] .
Quantification of MPO activity
Colon segments, stored at 80 ℃ were used with dosages of MPO and proinflammatory and anti inflammatory cytokines. The samples were homo genized in hexadecyltrimethylammonium bromide buffer (HTAB) (0.5% in 50 mmol/L sodium phosphate buffer, pH 6.0) that acts as a detergent, lysing granules of neutrophils containing MPO, which is released. The sample was centrifuged for 10 min at 4 ℃. The homogenate was subjected to a threefold freezing and thawing process to facilitate the rupturing of cell structures and the consequent release of the enzyme. On ELISA plates were placed 50 μL of supernatant from each sample and 150 μL of reaction buffer [23] . The results were expressed as MPO units per gram of tissue, where 1 U of MPO activity is defined as that degrading 1 μmol of hydrogen peroxide per min at 25 ℃.
Assessment of the involvement of pro-inflammatory (TNF-α and IL-1β ) and anti-inflammatory cytokines (IL-10)
TNFα, IL1β and IL10 levels were determined from colonic specimens, frozen in 80 ℃, and collected in the UC relapse model. For this, we used PBS buffer pH 7.4 (1:5) to homogenize the samples. The homogenate tubes were centrifuged at 12000 rpm for 10 min. The supernatants were frozen at 80 ℃ until assay. Subsequently, the samples were shaken in water bath at 37 ℃ for 20 min and then centrifuged at 10000 rpm for 5 min at 4 ℃. The supernatant was collected and the cytokines TNFα, IL1β and IL10 were quantitated treated with CdEtOHE at doses of 62.5 and 125 mg/kg (46 ± 12, p < 0.01 and 19 ± 8, p < 0.001 respectively) was observed compared to the colitic group (107 ± 38). In the experimental evaluation of the effect of CdHexP, a significant reduction was observed at doses of 31.25 and 62.5 mg/kg (52 ± 18, p < 0.01 and 21 ± 7, p < 0.001 respectively), when compared to the colitic animals (101 ± 45) ( Table 1) .
For the lesion score, CdEtOHE at doses of 62.5 and 125 mg/kg significantly reduced the amounts of lesion to 4.0 (15) (p < 0.05) and 3.0 (25) (p < 0.01) respectively, compared to the colitic control of 6 (57). CdHexP 31.25 and 62.5 mg/kg significantly reduced lesion to 5.0 (16) (p < 0.05) and 5.0 (45) (p < 0.01) respectively, compared to the colitic group of 7 (58) ( Table 1) .
A significant increase in weight/length for the colitic group (148 ± 17, p < 0.001, 154 ± 27, p < 0.001) was also observed when compared to the noncolitic group (110 ± 8, 102 ± 14 respectively). Treatment with different doses of CdEtOHE (31.25, 62.5, 125 and 250 mg/kg) did not reduce the weight/length ratio (152 ± 19, 146 ± 19, 134 ± 5 and 152 ± 14 respectively) for the parameter compared to the colitic group (148 ± 17). However, treatment with CdHexP at a dose of 62.5 mg/kg significantly reduced the ratio to 129 ± 20 (p < 0.05), compared to their respective colitic group (154 ± 27) ( Table 1) .
The administration of TNBS resulted in a diarrhea rate of 100% in the colitic animals. CdEtOHE at a dose of 125 mg/kg significantly reduced the diarrhea involvement to 14%. For CdHexP, treatment at dose of 62.5 mg/kg significantly reduced diarrhea to 29% (p < 0.05) when compared to their respective colitic control (87%) ( Table 1) .
Intestines of colitic, noncolitic and treated rats with different tested doses of CdEtOHE or CdHexP in the model can be seen in Figures 1 and 2 respectively.
Investigation of Cd-EtOHE and Cd-HexP effects in chronic phase intestinal inflammation with induced relapse using TNBS in rats
A significant reduction in macroscopic damage scores was observed for both CdEtOHE (125 mg/kg) and Cd HexP (62.5 mg/kg), to 1.0 (14) (p < 0.05) and 1.0 (14) (p < 0.01) respectively, compared to the colitic control 4 (36) . Moreover, the tested plant sample reduced the onset of diarrhea by 56% when compared to colitic animals (94%) (see Table 2 ).
The weight/length ratio significantly increased in the colitic, CdEtOHE and CdHexP groups (143 ± 14, p < 0.001; 132 ± 11, p < 0.001; 122 ± 12, p < 0.01, respectively) compared to the noncolitic group (97 ± 9). However, CdHexP 62.5 mg/kg caused a significant reduction (122 ± 12, p < 0.01), compared to the colitic group (143 ± 14). These results are shown in Table 2 , and can be seen best in Figure 3 .
A significant decrease in water (28 ± 3, p < 0.01) and food (19 ± 2, p < 0.01) intake was observed in the colitic group, compared to the noncolitic animals (31 ± 4 and 22 ± 2 respectively). Only treatment with CdHexP increased water (31 ± 2, p < 0.05) and food (22 ± 3, p < 0.01) intake, compared to colitic animals (28 ± 3, p < 0.01 and 19 ± 2, p < 0.01 respectively) ( Table 3) .
As an additional parameter to the data described above, we evaluated the effect of repeated admini strations of CdEtOHE (125 mg/kg) and CdHexP (62.5 mg/kg) on the body weights of animals affected with intestinal inflammation. At the end of the experiment, there was a significant reduction in mean body weight for the colitic group (215 ± 21, p < 0.001) when compared to the noncolitic group (261 ± 35). However, when the treatments were performed with CdHexP (62.5 mg/kg), a significant increase in mean body weight (239 ± 17, p < 0 05) was observed compared to the colitic animals (215 ± 21) ( Table 4) .
A significant increase was observed in spleen weight in the colitic group (2.8 ± 0.5, p < 0.05) compared to the noncolitic group (2.1 ± 0.2). Analyzing the organs of animals treated with CdEtOHE or CdHexP, a significant increase in spleen weight for animals treated with CdEtOHE as compared to the noncolitic group was demonstrated (Table 5 ). In other evaluations (heart, liver and kidneys) no significant changes, compared to the noncolitic group, were observed.
Histological analysis
Histological examination of the colon of noncolitic rats showed normal histological structure, highlighting the structure of the mucosal straight intestinal glands with large numbers of goblet cells and lamina propria classical (or normal). The animals belonging to the colitic group had transmural inflammation, necrosis of the mucosa with disruption of glands, and loss of goblet and epithelial cells. The presence of granulation, highlighting neutrophilic and lymphocytic infiltration, was also observed.
Treatment with CdEtOHE (125 mg/kg) or CdHexP (62.5 mg/kg) maintained some areas of the mucosal structure and epithelium intact, reducing the reducing the Inflammatories cells in lamina propria as compared to the colitic group, suggesting the reepithelialization of the animals treated with the vegetable samples ( Figure 4 ).
Quantification of MPO activity
According to the results obtained, there was a significant increase in MPO to 40.270 ± 3.077 (p < 0.001) in the colitic group when compared to noncolitics (10.120 ± 1.672). When compared to the colitic controls (40.270 ± 3.077), treatments with CdEtOHE (15.187 ± 1.158, p < 0.001) or CdHexP (17.620 ± 2.395, p < 0.001) significantly reduced MPO ( Figure 5) . 
Assessment of the involvement of pro-inflammatory (TNF-α and IL-1β ) and anti-inflammatory cytokines (IL-10)
The results showed a significant increase in TNFα levels in colitic animals (2.0 ± 0.2, p < 0.01) compared to noncolitics (1.3 ± 0.1). However, the treatment of CdEtOHE (125 mg/kg) or CdHexP (62.5 mg/kg) resulted in TNFα level reduction (1.2 ± 0.2 and 1.4 ± 0.1, p < 0.01) respectively, compared to the colitic group (2.0 ± 0.2) ( Figure 5 ). IL1β levels increased in colitic animals (63 ± 6, p < 0.001) when compared to the noncolitic group (32 ± 4.0). Treatment with CdEtOHE significantly reduced to 41 ± 5 (p < 0.01) IL1β, compared to the colitic group (63 ± 6.2). CdHexP did not cause significant change when compared to the negative control ( Figure 5) .
The results showed significant reduction of IL10 in intestinal tissues, comparing the colitic group 3. 
Immunohistochemical analysis (COX-2, PCNA and SOD expression)
In analyzing the results of COX2 expression shown in Table 6 and Figure 6 , we observed a significant increase in COX2 expression in the colitic group animals to 505 (1001450) (p < 0.05) when compared the noncolitic group of 230 (110700). However, treat ment with CdEtOHE (125 mg/kg) or CdHexP (62.5 mg/kg) significantly reduced the expression of COX2 to 90 (102590) (p < 0.001) and 205 (20790) (p < 0.001) respectively, compared to the colitic group of 505 (1001450).
A significant increase in PCNA expression was observed in the animals of the colitic group of 5380 (85015960) (p < 0.001) when compared to the noncolitic group of 1425 (607890). However, treat ment with CdEtOHE (125 mg/kg) or CdHexP (62.5 mg/kg) significantly reduced PCNA expression to 1. 0.001) respectively, compared to 5.380 of the colitic group (85015960) (p < 0.001) ( Table 6 and Figure 6 ).
The results of this analysis demonstrated a sig nificant decrease in the expression of SOD in colitic controls to 165 (101000) (p < 0.001) when compared to the noncolitic group of 400 (801115). The treat ment of the animals with CdEtOHE (125 mg/kg) or CdHexP (62.5 mg/kg) increased the expression of SOD to 400 (501480) (p < 0.05) and 435 (201650) (p < 0.001) respectively, compared to the colitic control (Table 6 and Figure 6 ).
DISCUSSION
A promising area for research, many plant species and their chemical constituents exert therapeutic actions. This has led to the development of new, effective and safe drugs for the treatment of various pathological processes. There is also an interest in targeted therapy for diseases derived from oxidative stress, such as IBD [11, 25] . IBDs are progressive and destructive chronic disorders of the GI tract, the most common being CD or UC. There is evidence that the pathogenesis of IBD is related to a dysfunctional interaction between the bacteria of the intestinal microflora and mucosal immune system [26, 27] . CD and UC are immunologically different diseases. CD is characterized by an exaggerated cellular Th1 response (CD4+) and Th17, characterized by high levels of INFγ/IL17 and IL12/IL23. UC is characterized by a heightened Th2 response, and excessive IL5 and IL13 [2830] . TNBS is a hapten, administered by enema in rats in combination with 50% ethanol to break the mucus barrier and facilitate penetration of the hapten into the intestinal epithelium. TNBS reacts with autologous proteins and stimulates the development of hypersensitivity, leading to the activation of antigen specific T cells. The immune response induced by the hapten causes severe ulceration of the mucosal and epithelial barrier, characterized by transmural infiltration of mononuclear cells [20] . Preventive treatment with CdEtOHE (62.5 to 125 mg/kg) or CdHexP (31.25 and 62.5 mg/kg) caused a significant reduction in the severity and extent of injury as reflected in the macroscopic lesion score. The macroscopic/microscopic damage scores and colon weight/length ratio can be considered as sensitive and reliable markers to estimate the severity of the disease, and thus the antiinflammatory effect promoted by the test drug [31] . A low incidence of diarrhea in animals treated with CdEtOHE and CdHexP was also observed. Diarrhea is a major symptom of disease in both animals and humans and indicates loss of the absorptive capacity of the colon, which is impaired in intestinal infla Values are expressed as mean ± SD (n = 7-9). One-way ANOVA, followed by Dunnett's test, a P < 0.05 and b P < 0.01 vs colitic group; [32] . The results suggest that treatment with the plant samples restored the intestinal absorptive capacity.
CdHexP at 62.5 mg/kg significantly reduced the weight/length ratio. This effect is possibly related to the scavenging capacity of free radicals caused by treatment at this dose [33] . These results demonstrate, for the first time, antiinflammatory intestinal activity for a species belonging to the genus Combretum.
The more effective doses of CdEtOHE (125 mg/kg) or CdHexP (62.5 mg/kg) were selected to investigate their effects in the chronic phase with relapse in TNBS induced UC in rats. This model mimics the disease in humans and can be used to evaluate new treatments potentially applicable in IBD [31] . CdEtOHE at 125 mg/kg or CdHexP at 62.5 mg/kg Intestinal inflammation in the TNBSinduced model promoted the loss of 8% to 10% of body weight notably at 1 wk after induction, this is related to reduction in food intake due to abdominal pain and diarrhea during the active phase of the disease [34] . Treatment with CdHexP at 62.5 mg/kg reversed low water and food intake (and body weight loss) caused by disease.
The spleen recycles and acts as a reserve of red blood cells. The organ is the center of reticulo endothelial system activity, and is an essential part of the immune system [35] . A significant increase in spleen weight of colitic animals when compared to noncolitic animals was demonstrated. UC and CD are mentioned in lists of factors that can cause increased spleen size, which can occur through lymphoid cell accumulation in immune functions [35, 36] . MPO is an enzyme found in neutrophils and has been used as a quantitative index of neutrophil influx into inflamed intestines. The recruitment and activation of neutrophils results in a significant increase in free radical production, capable of overcoming antioxidant protections, and resulting in oxidative stress and inflammation [37, 38] . CdEtOHE at 125 mg/kg and Cd HexP at 62.5 mg/kg significantly decreased MPO activity when compared to colitic animals. This may de Morais Lima GR et al. Combretum duarteanum The inflammation in the TNBSinduced colitis model is characterized by a Th1 pathway immune response, in which there is an increase in TNFα, IL1β, IL12, IL17, IL18 and IL6 [3941] . Upregulation of the inflammatory state with increased TNFα and IL1β levels in colitic rats was observed, which corroborates the literature findings [42] . The treatment with CdEtOHE at 125 mg/kg or CdHexP at 62.5 mg/kg was able to significantly reduce TNFα levels when compared to the colitic controls, suggesting that TNFα suppression is related to the antiinflammatory effect promoted by the vegetable samples studied. CdEtOHE at 125 mg/kg was able to decrease IL1β levels, suggesting that compounds of this plant sample may interfere with the synthesis machinery of IL1β activation by inhibiting production [10, 43, 44] . IL10 suppresses production of proinflammatory cytokines, such as IL12, IL6, IL1 and TNFα, in activated macrophages in vitro, and blocks the ability of macrophages stimulating the production of interferon by Th1 cells. IL10 is produced in large amounts by TCD4+ regulatory cells subtype (Tregs). Tregs maintain homeostasis by suppressing the adaptive response of T cells and preventing autoimmunity [45] . A significant elevation in IL10 levels in animals treated with CdEtOHE at 125 mg/kg or CdHexP at 62.5 mg/kg, compared to the colitic group, was demonstrated. This increase is attributable to compensatory mechanisms against colonic injury, possibly playing a role in reducing mucosal inflammation and preventing it from becoming uncontrolled. IL10 downregulates antigen presentation, and thereafter the release of proinflammatory cytokines such as TNFα, IL1β and IL6 [46, 47] . Studies have shown that COX2 is expressed predominantly in experimental colitis. Colotic humans and animals show considerable improvement in the inflammatory process when COX2 inhibitors are used [48] . The vegetable samples tested prevented the increase in expression of this enzyme, and suggest that the intestinal antiinflammatory effect promoted by CdEtOHE at 125 mg/kg or CdHexP at 62.5 mg/kg is mediated by a reduction in COX2 expression.
PCNA is an intranuclear protein, whose expression is related to cell proliferation and DNA repair. It is highly expressed during the S phase of the cell cycle [49] . Studies show that PCNA expression is up regulated during chronic inflammation, inducing the proliferation of epithelial cells to repair the mucous tissue [50, 51] . The positive expression of PCNA was increased in colitic animals in this study, while CdEtOHE at 125 mg/kg or CdHexP at 62.5 mg/kg treatment significantly decreased expression of this protein. SOD is a key enzyme that converts superoxide to H2O2, a more stable metabolite. During oxidative stress and inflammation, SOD activity is decreased in inflamed tissues as compared to noninflamed tissues. The decreased SOD activity allows superoxide accumulation and subsequent oxidative effects in the intestinal tissue, as well as increased expression of adhesion molecules [52] . Treatment with CdEtOHE at 125 mg/kg or CdHexP at 62.5 mg/kg significantly increased the expression of this enzyme when compared to colitic animals, suggesting involvement of an antioxidant effect in the intestinal antiinflammatory activity promoted by the vegetable samples.
In conclusion, C. duarteanum presents promising antiinflammatory intestinal effects that are related to reduced levels of the proinflammatory cytokines (TNFα and IL1β) and increased antiinflammatory cytokine (IL10), which feature regulatory effects on the immune response, with reduction in the expression of COX2, PCNA, and an increase in the antioxidant enzyme SOD.
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Background
A variety of herbal medicines have been shown to produce promising results in the treatment of peptic ulcer and inflammatory bowel disease. Combretum duarteanum (C. duarteanum, Cd), the species selected for this study, is popularly known as "mufumbo, cipiúba, cipaúba". In folk medicine, it is used to treat pain, inflammation and gastrointestinal (GI) tract disorders. Given the need for new inflammatory bowel disease therapies, this study aimed to evaluate, for the first time, the intestinal anti-inflammatory activity promoted by the species C. duarteanum, validating its popular use and contributing to the search for new therapies for diseases that affect the GI tract.
Research frontiers
C. duarteanum has presented in vitro and in vivo anti-inflammatory, antinociceptive and antioxidant capacities. Furthermore, it has demonstrated low toxicity, gastroprotective and antiulcer activity in different models of acute ulcer induction (acidified ethanol, ethanol, nonsteroidal anti-inflammatory drugs, stress, pylorus ligature and acetic acid) in animals.
Innovations and breakthroughs
This study evaluated, for the first time, the intestinal anti-inflammatory activity promoted by the species C. duarteanum Cambess.
